Orion Pharma (DHA:ORIONPHARM) Inventories, Finished Goods: BDT179 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONPHARM Orion Pharma Ltd DHA:ORIONPHARM
72 GF Score
Price BDT29.90
GF Value BDT20.16
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orion Pharma Inventories, Finished Goods?

Orion Pharma DHA:ORIONPHARM -1.32% 72 Inventories, Finished Goods is BDT179 Mil as of Mar. 2026. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 72/100 and a GF Value™ of BDT20.16 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Orion Pharma's quarterly finished goods increased from Sep. 2025 (BDT139 Mil) to Dec. 2025 (BDT186 Mil) but then declined from Dec. 2025 (BDT186 Mil) to Mar. 2026 (BDT179 Mil).

Orion Pharma's annual finished goods increased from Jun. 2023 (BDT0 Mil) to Jun. 2024 (BDT152 Mil) and increased from Jun. 2024 (BDT152 Mil) to Jun. 2025 (BDT171 Mil).

Orion Pharma Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Orion Pharma's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Pharma Inventories, Finished Goods Chart

Orion Pharma Annual Data
Trend Dec14 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 92.88 120.19 0.00 152.49 170.59

Orion Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 158.00 170.59 138.54 185.55 178.75
DHA:ORIONPHARM
72GF Score
Orion Pharma Ltd DHA:ORIONPHARM
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Pharma Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of BDT179 Mil mean?
Orion Pharma (DHA:ORIONPHARM) has a Inventories, Finished Goods of BDT179 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Orion Pharma and its competitors.
Is Orion Pharma's Inventories, Finished Goods too high?
Orion Pharma's current Inventories, Finished Goods is BDT179 Mil. Overall, Orion Pharma has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Inventories, Finished Goods compare to CEG and VST?
Orion Pharma's Inventories, Finished Goods of BDT179 Mil can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for an Utilities - Independent Power Producers company?
A good Inventories, Finished Goods depends on the Utilities - Independent Power Producers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Orion Pharma and its competitors. Orion Pharma's current Inventories, Finished Goods is BDT179 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.16, compared to a current price of BDT29.90 — trading 48.3% above its estimated fair value. The current Inventories, Finished Goods is BDT179 Mil. Orion Pharma's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Inventories, Finished Goods is BDT179 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued. The current stock price of BDT29.90 is trading 48.3% above its estimated GF Value™ of BDT20.16. GuruFocus considers Orion Pharma to be Significantly Overvalued.

Key valuation signals for DHA:ORIONPHARM:

  • Inventories, Finished Goods: BDT179 Mil
  • GF Value™: BDT20.16 vs. price of BDT29.90 (48.3% above fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Pharma Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
72GF Score

Get the complete analysis for DHA:ORIONPHARM

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT29.90
Price
BDT20.16
GF Value